Ab­b­Vie’s Rin­voq pass­es PhI­II AD test; Dicer­na races Al­ny­lam; New Sarep­ta gene & cell col­lab

→ Al­most a year af­ter it was ap­proved for rheuma­toid arthri­tis, Ab­b­Vie’s JAK in­hibitor Rin­voq was shown for the first time to work as a monother­a­py in atopic der­mati­tis. In a Phase III study, two dif­fer­ent dos­es of the drug beat place­bo on all pri­ma­ry and sec­ondary end­points. Of pa­tients in the high dose group, 80% saw at least 75% skin clear­ance ver­sus 16% for place­bo. That num­ber was 70% in the low dose group.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.